Biogen announces that the European Commission has granted marketing authorization for its Skyclarys (omaveloxolone) for the treatment of Friedreich's ataxia in adults and adolescents over the age of 16.

Skyclarys is the first treatment indicated in the European Union for this rare, genetic, disabling and life-shortening neurological disease. The treatment has demonstrated benefits for patients, compared to a placebo.

'Our team is committed to working with the medical community and health authorities across the EU to enable urgent access to treatment for patients,' says Priya Singhal, Biogen's Global Head of Development.

Copyright (c) 2024 CercleFinance.com. All rights reserved.